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Neural and behavioural changes in male periadolescent mice
after prolonged nicotine-MDMA treatment
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Oluwamolakun O. Bankole3 & Philemon D. Shallie4 & Olalekan M. Ogundele2,3
# Springer Science+Business Media New York 2015
Abstract The interaction between MDMA and Nicotine af-
fects multiple brain centres and neurotransmitter systems (se-
rotonin, dopamine and glutamate) involved in motor coordi-
nation and cognition. In this study, we have elucidated the
effect of prolonged (10 days) MDMA, Nicotine and a com-
bined Nicotine-MDMA treatment on motor-cognitive neural
functions. In addition, we have shown the correlation between
the observed behavioural change and neural structural chang-
es induced by these treatments in BALB/c mice. We observed
that MDMA (2 mg/Kg body weight; subcutaneous) induced a
decline in motor function, while Nicotine (2 mg/Kg body
weight; subcutaneous) improved motor function in male
periadolescent mice. In combined treatment, Nicotine reduced
the motor function decline observed in MDMA treatment,
thus no significant change in motor function for the combined
treatment versus the control. Nicotine or MDMA treatment
reduced memory function and altered hippocampal structure.
Similarly, a combined Nicotine-MDMA treatment reduced
memory function when compared with the control.
Ultimately, the metabolic and structural changes in these neu-
ral systems were seen to vary for the various forms of treat-
ment. It is noteworthy to mention that a combined treatment
increased the rate of lipid peroxidation in brain tissue.
Keywords MDMA .Nicotine .Motor cortex . Striatum .
Hippocampus . Behaviour
Introduction
MDMA, also known as Bmolly^ or Becstasy ,^ is the most
widely used synthetic drug among adolescent humans which
represents a major percentage of illicit drug users (NIH-NIDA
2013; Azagba et al. 2014). It holds central and peripheral
nervous system effects such as increased heart rate, empathy
towards others, blur vision, increased libido and suppression
of hunger (Teixeira-Gomes et al. 2014; Kwack et al. 2014;
Downey and Loftis 2014; Kiyatkin et al. 2014, 2015; Fulceri
et al. 2011). Most of these effects have been attributed to the
ability ofMDMA tomodulate neurotransmitter activities, spe-
cifically dopaminergic (DA) (Izco et al. 2007; Palfreyman
et al. 1993), serotoninergic (5-HT) (Lizarraga et al. 2014;
Homberg et al. 2007) and glutamergic signalling in multiple
brain centres involved inmotor coordination, anxiety and cog-
nitive functions (Meamar et al. 2012; Anneken et al. 2013;
Sarkar and Schmued 2010). MDMA is known to facilitate the
release of serotonin (5-HT), followed by inhibition of its re-
uptake in synaptic terminals (Lizarraga et al. 2014).Similarly,
it blocks dopaminergic re-uptake in dopaminergic (DA) neu-
rons; but to a lesser extent when compared to its effect at 5-HT
terminals (Seger 2010; Rouine et al. 2014; Roger-Sánchez
et al. 2013). Despite the effect of MDMA on multiple
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neurotransmitter systems, most of its action is known to be
mediated through its effect on the serotoninergic (5-HT) sys-
tem (Rouine et al. 2014; Roger-Sánchez et al. 2013).
Furthermore, MDMA facilitates the oxidative deamination
of monoamines (5-HT and Dopamine) leading to the produc-
tion of reactive oxygen species (ROS), reactive nitrogen spe-
cies (RNS) and auto-oxidation (Karuppagounder et al. 2014;
Fornai et al. 2002). As a result of these effects, MDMA causes
cellular oxidative stress and lipid peroxidation.
Aside the effects of MDMA on neurotransmitter re-uptake
and induced oxidative stress, studies have shown that MDMA
can act as a partial agonist for nicotinic acetylcholine receptors
(α7 nAChRs) at neuromuscular junctions (Garcia-Ratés et al.
2010; Chipana et al. 2008; Ciudad-Roberts et al. 2014;
Nuutinen et al. 2005); thus generating effects similar to the
actions of nicotine at nicotinic neuromuscular junctions
(Lettfuss et al. 2013; Pubill et al. 2013; Escubedo et al.
2009). In addition, use of nicotine analogues up regulates
the expression of nicotinic receptors; thus, MDMA (a partial
agonist) and nicotine (agonist) combined use can facilitate
over expression of nicotinic receptors causing neurotoxicity
through increased receptor sensitivity (Ciudad-Roberts et al.
2014; Pubill et al. 2013).
Similar to MDMA, nicotine also acts centrally through
potentiation of cholinergic receptors, alteration of 5-HT and
dopaminergic neurotransmission (Matsuura and Urushihata
2014; Guy and Fletcher 2014; Wang et al. 2014). As a result
of nicotinic modulation of dopaminergic D2 receptor stimula-
tion, nicotine increases dopaminergic activity in the
nigrostraitum; thus facilitating motor activities in the central
nervous system (Wang et al. 2014; Cosgrove et al. 2014).
Nicotine also potentiatesα7 nAChRs at the nicotinic neuromus-
cular junctions to increase motor function peripherally (Kiss
et al. 2014; Vu et al. 2014; Kiguchi et al. 2012). Although
dopaminergic stimulation accounts for the central increase in
motor function seen in nicotine use, it is also responsible for
the brain reward effects; which, in part, causes addiction to
nicotine after chronic use (Wang et al. 2014; Wing et al. 2014).
In this study we examined the effect of Nicotine, MDMA
and a combined Nicotine + MDMA treatment on motor-
cognitive function of periadolescent mice. This was aimed at
showing the effect of early life (periadolescent) exposure on
the behaviour of these animals during the final postnatal de-
velopment of the motor-cognitive neural systems. In addition,
we have shown the correlation between the observed behav-
ioural changes and cellular changes observed in the
corticostriatum and hippocampus.
Materials and methods
Materials BALB/c breeder Mice were obtained from the an-
imal holding facility of Afe Babalola University, Nigeria.
Nicotine salt was a generous gift from Dr. Anna DeLuca of
the University of Cagliari, Italy. MDMA crystals was obtained
from the Nigerian Drug Law Enforcement Agency (NDLEA),
Lagos, Nigeria. All enzyme assay kits (ALP, SOD, MDA and
GPx), Formalin, sucrose, sodium chloride and picric acid were
procured from Sigma-Aldrich, Germany.
Animal preparation N = 20 (P.21) periadolescent male
BALB/c mice were bred in the animal holding facility of the
Afe Babalola University, Nigeria. The animals were housed
under standard laboratory conditions of alternating light/dark
and were fed ad libitum. Animals were randomly divided into
four groups of n = 5 animals and labelled as appropriate. All
protocols were in accordance with the IACUC animal
use guidelines and were approved by the Animal Use
Ethical Committee of the Afe Babalola University,
Nigeria.
Treatment Male periadolescent mice (P.21) were treated for a
period of 10 days with the vehicle, Nicotine, MDMA and
Nicotine + MDMA. The control group received normal saline
(subcutaneous). MDMAwas administered subcutaneously to
a set of n = 5 animals (2 mg/Kg body weight) at two days
interval. The Nicotine treated group received 2 mg/kg BW
of Nicotine daily while the Nicotine-MDMA group was treat-
ed with Nicotine (2mg/Kg BW; s.c.) daily andMDMA (2mg/
Kg; s.c.) at 2 days interval. The total duration of treatment for
all groups was 10 days.
Body weight measurement The body weight of all animals
in each group was taken daily to determine the average
weight/group/day for 10 days. The change in body weight
for the control and treatment groups was determined in linear
regression analysis to determine the P value and level of sig-
nificance at 95 % Confidence Interval (GraphPad Prism
Version 5).
Behavioural tests Behavioural studies commenced on the
last treatment day (P.31) and extended till the day after the last
treatment (P.32). The animals were moved to the behavioural
testing room 24 h prior to the commencement of tests
(acclimatization) (Fig. 1a).
Rotarod test This was done to measure motor activity as a
function of latency of fall (LOF) on the treadmill. Each animal
was placed on the rotating bar of the Rotarod following which
the speed was gradually increased from 3 to 35 rpm over a
period of 3 min. The duration spent on the Rotarod (before
fall) was measured to determine the LOF. In this study, each
animal was tested in three consecutive trials (T1, T2 and T3)
with an inter-trial time of 30 min. Subsequently, we deter-
mined the average LOF/animal/group and compared the treat-
ment groups with the control.
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Parallel bar test Two metal bars, each 1 m long and 2 mm
thick, were placed on an elevated wooden platform 60 cm
high above a padded floor. The metal bars were equidistant
to each other (3 cm apart) throughout the length of the appa-
ratus. Subsequently, the animal was placed perpendicular to
the axis of the metal bars at the midpoint of their length (0.5 m
mark). With the use of a timer, the duration (seconds) for each
animal to complete a 90° turn on the double bar was recorded
(latency of turn; LOT). Similarly, we determined the time
taken for an animal to cover 0.5 m to one end of the bars. In
subsequent analysis, we compared the LOTand the time taken
to cover 0.5 m on the metal bars (as described earlier) for the
control and treatment groups.
Y-Maze test for motor function The Y-Maze set up was
placed in an isolated sound-proof room with adequate illumi-
nation. The animals (mice) were gently placed into the central
triangle of the Y-Maze and allowed to explore the three arms
A, B and C of the maze 10min following which the video was
analysed to determine the frequency of arm entries for each
arm of the maze. Subsequently, we determined the frequency
of alternation between the three arms of a Y-Maze (A, B and
C) as a measure of exploratory motor function associated with
spatial working memory. The total number of arm entries/an-
imal/group was determined and compared for the control and
treatment groups.
Y-Maze test for memory function Using the procedure de-
scribed above for Y-Maze, we estimated spatial working
memory function for the control and treatment groups. The
memory index was presented as a function of the percentage
alternation between successive arms of the maze
numberof RightDecisions=totalarmentries−2 100ð Þ.
Novel object recognition test (NOR) This was done to mea-
sure the non – spatial working memory in the control and
treatment groups. Each animal was subjected to two tests T1
and T2 for 4 min each; an inter-trial time of 60 min was ob-
served between T1 -T2. In T1 the animals were allowed to
explore two identical objects for 4 min following which the
animals were returned to their cages. The animals spent the
inter-trial interval in their cages following which they were
(a)
(b)
Fig. 1 a Schematic illustration of
behavioural tests for motor and
memory function b Scatter plot
showing daily weight change for
10 days (acute treatment). The
control group recorded a steady
increase in body weight for the
treatment duration; with a P value
of 0.8333. MDMA treatment
caused a significant decrease in
body weight when compared to
the control (P = 0.0476;
Significant at *P < 0.05) at 95 %
confidence interval. However, the
Nicotine (P = 0.4048) and
Nicotine-MDMA (P = 0.9603)
treatment showed no significant
change in body weight over this
period when compared with the
control. The Nicotine and
Nicotine-MDMA treatment
groups recorded an increase in
body weight between Day 3 and 7
when compared with the control;
a decline in body weight was
observed thereafter (Day 8–10)
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returned to the testing area for the second test T2 (4 min). In
T2, one of the old objects (familiar objects) was replaced by a
new object (novel object). The animals explored the objects
for 4 min while the scientists recorded the time spent explor-
ing the old and novel objects respectively. The memory index
was calculated thus;
TimeSpentonNewObject
Timespentof Newobjectþ TimespentonOldObject  100
Oxidative stress and lipid peroxidation markers Whole
brain tissue was preserved in cold 0.25 M Sucrose at 4 °C
and homogenized using a mortar and pestle. Subsequently,
the tissue homogenates were centrifuged at 3000 rpm and
the supernatant was collected for colorimetric assay of GPx
(glutathione peroxidase), SOD (superoxide dismutase),
MDA (Malondialdehyde) and ALP (alkaline phospha-
tase) using the appropriate kits. All assay protocols
were in accordance with the manufacturer’s specifica-
tions and guidelines.
Oxidative protein damage The total protein content in the
brain homogenate was measured using the Biuret method
(Kingsley 1939) to determine the extent of oxidative protein
damage in animals treated with Nicotine, MDMA and
Nicotine + MDMA.
Histology The animals were anaesthetized with Ketamine
(100 mg/Kg) and Diazepam (5 mg/Kg) (intraperitoneal) fol-
lowing which a transcardial perfusion was done through the
left ventricle using normal saline. Subsequently, a freshly pre-
pared perfusion fixative [90 ml of 10% Formalin and 90ml of
Picric acid] was injected gradually through the left ventricle
with the animal inverted (gravity) to percolate the cranial cav-
ities and cerebral blood vessels. The whole brain was then
removed and fixed overnight in the perfusion fixative; follow-
ing which it was transferred into a cryopreserving fixative
[240 ml of 10 % Formalin and 30 % Sucrose] at 4 °C for
48 h. Coronal (whole brain) sections were obtained using
stereotaxic markings to expose the various neural systems of
interest. Tissue sections taken at 0.84 mm anterior to the breg-
ma revealed the motor cortex (M1), the striatum (CPu) and the
medial forebrain bundle (mfb). At 1.71 mm anterior to the
bregma, the various part of the hippocampus were seen;
CA1, CA2, CA3 and dentate gyrus (DG). The amygdaloid
area and anterior amygdaloid nucleus (AAn) were shown at
0.72 mm anterior to the bregma. Tissue processing was done
routinely to obtain paraffin wax embedded sections stained in
Haematoxylin and Eosin.
Cell count Histological images were acquired using
Cameroscope (5.1 MP) connected to an Olympus Binocular
Research Microscope (Olympus, New Jersey, USA.
Subsequently, the images were rendered in grayscale using
Image J (NIH, USA). The cells were counted at different mi-
croscopic fields (n = 7) for n = 5 sections for all groups using
the method of Going (1994). Cell count score was analysed in
One-way ANOVA (with Tukey post-hoc test) and expressed
in a bar chart (mean) with error bar (SEM).
Statistical analysis For the body weight, brain weight, be-
havioural studies, cell count and enzyme assays, data were
analysed in one way ANOVA, with Bon Ferroni post-hoc test.
The outcome for the control, Nicotine, MDMA and Nicotine
+ MDMA treatments were compared and presented in a bar
chart (mean) with error bars (standard error of mean). The
values were considered significant at *P < 0.05, **P < 0.01
and ***P < 0.001.
Results
Body weight
The effect of Nicotine, MDMA and Nicotine + MDMA treat-
ment on the body weight was measured daily for a duration of
10 days. No significant change in body weight was recorded
for the Nicotine (P = 0.4048) and Nicotine-MDMA (P =
0.9603) treatment groups. However, the MDMA (P =
0.0476*) treated animals recorded a significant decrease in
body weight when compared with the control (P = 0.8333)
at 95 % confidence interval (*P < 0.05). Generally, a fluctua-
tion in body weight was seen in the treatment groups while the
control recorded a steady increase in body weight for this
duration (Fig. 1b). Between Days 3 and 8, the control group
showed a steady rise in body weight; similarly, Nicotine and
Nicotine-MDMA treatment recorded an increase in weight
higher than that of the control. During this phase, the
MDMA treatment group recorded a sharp decline in body
weight when compared with the control, Nicotine and
Nicotine-MDMA treatments (Fig. 1b).
Motor function and coordination
Rotarod test for motor function The latency of fall (LOF)
was determined to measure motor function in the treatment
and control groups after prolonged treatment with Nicotine,
MDMA and Nicotine + MDMA. The Nicotine treatment
group recorded the most significant increase in motor function
when compared with the control (P < 0.05*). Although no
significant change in LOF was recorded when MDMA was
compared with Nicotine treatment, however, the Nicotine
treatment groups recorded a significant LOF versus the
Nicotine-MDMA treatment (P < 0.01**). Thus, nicotine treat-
ment improved motor function (increased LOF) when com-
pared with the control and other treatment groups (Fig. 2).
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Parallel bar test for motor coordination The time taken for
an animal to turn on two raised parallel bars was analysed to
determine the latency of turn (LOT; motor coordination).
Similar to our observations in the Rotarod test, the Nicotine
treatment group had a LOT value higher than the control
(P < 0.05*) while MDMA recorded a significant decrease in
LOTwhen compared with the Nicotine treatment (P < 0.001*)
and Nicotine-MDMA treatment (P < 0.01**) (Fig. 3a). In the
same test, the frequency of lateral movement on the bar was
determined to measure motor function in the animals. Similar
to our observations in the LOT, the Nicotine treatment group
showed no significant change in motor coordination while
MDMA (P < 0.01**) and Nicotine-MDMA (P < 0.05*) re-
corded a significant decrease in motor coordination versus
the control (increased speed of movement on bar; Fig. 3b). It
is noteworthy, to mention that the most significant decline in
motor function and coordination was seen in the MDMA
treatment group.
Y-Maze test for motor function Motor activity, associated
with spatial working memory, was measured as a function of
total number of arm entries in Y-Maze (frequency of arm
alternation). No significant change was observed when the
treatment groups were compared with the control. However,
the Nicotine treatment group recorded the highest number of
entries and was significant when compared with the MDMA
treatment (P < 0.05*) (Fig. 4a).
Memory and cognitive function
Y-Maze test for memory function The percentage alterna-
tion between the arms of the Y-Maze was analysed to
determine the spatial working memory for the control and
treatment groups. No significant change was seen when a
treatment group was compared with other treatment groups
and control (Fig. 4b).
Novel object recognition This was done to measure non –
spatial working memory in treated animals (10 days treatment
duration). MDMA, Nicotine and Nicotine-MDMA treatments
caused a decline in memory function when compared with the
control. Treatment with MDMA caused a significant decrease
in memory function when compared with the control
(P < 0.001). Interestingly, the Nicotine treatment group
showed a less significant decline in memory function versus
the control (P < 0.05*) when compared with MDMA versus
the control (P < 0.001***). Similar to the outcome of MDMA
treatment, when Nicotine was co-administered with MDMA,
a decline in memory function was also observed versus the
control (P < 0.01**) (Fig. 5a). Thus, we inferred that MDMA
administered singly or combined with Nicotine facilitated a
decline in memory function.
Oxidative stress markers
Total protein content MDMA or Nicotine treatment caused
an increase in protein content in the brain tissue homogenate
when compared with the control (P < 0.001). No significant
change in total protein was seen when Nicotine was compared
with MDMA; similarly, a combined Nicotine-MDMA treat-
ment caused no significant change versus the control. In ad-
dition, Nicotine-MDMA total protein content was lower than
the values recorded for either Nicotine or MDMA treatment
(P < 0.001) (Fig. 6a). We deduced from these outcomes that
Nicotine or MDMA treatment increased total protein content
in brain tissue while a combined Nicotine-MDMA treatment
had no effect on protein content after a prolonged treatment
duration.
Oxidative stress Nicotine treatment caused a significant in-
crease in percentage superoxide dismutase (SOD) when com-
pared with the control (P < 0.05) while MDMA and Nicotine-
MDMA caused no change in SOD expression versus the con-
trol. These findings suggests that Nicotine treatment induced
mitochondrial stress and radical formation (increased SOD)
while MDMA did not increase radical level for this period
of treatment. Going further, co-treatment of Nicotine-
MDMA caused no significant increase in SOD levels
(radical); suggesting that MDMA blocks the radical formation
pathway utilized by nicotine (Fig. 6b).
Lipid peroxidation Although, Nicotine-MDMA treatment
caused no significant change in SOD level and total protein
when compared with the control, this treatment group was
characterized by an increase in neuronal lipid peroxidation
Fig. 2 Rotarod test for motor function; latency of fall (LOF). The highest
LOF was recorded in the Nicotine treated animals (P < 0.05) when
compared with the control. MDMA and Nicotine-MDMA treatments
caused no significant change in LOF when compared with the control.
Although no significant change was seen when Nicotine was compared
with MDMA treatment, however, Nicotine treatment caused a significant
increase in motor function (LOF) when compared with the Nicotine-
MDMA treatment (P < 0.01**)
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versus the control (P < 0.05) (Fig. 6c). Subsequent analysis
involving GPx assays show that Nicotine-MDMA treatment
also increased the level of GPx; further confirming an increase
in the rate of lipid peroxidation (Fig. 6d). Similar to our ob-
servation in MDA analysis, the MDMA or Nicotine treatment
group recorded a lower GPx value (reduced rate of lipid per-
oxidation) when compared with the control (P < 0.05)
(Fig. 6d).
ALP After Nicotine treatment, no significant change in ALP
level was observed while MDMA increased ALP when com-
pared with the control (P < 0.001). Although, nicotine did not
significantly alter ALP levels, a combined Nicotine-MDMA
treatment increased ALP significantly when compared with
MDMA (P < 0.001), Nicotine (P < 0.001) and the control
group (P < 0.001) (Fig. 6e).
In summary, Nicotine-MDMA treatment caused no notable
change in total protein/SOD but caused an increase in lipid
peroxidation (MDA/GPx/ALP). On the other hand Nicotine
increased total protein and SOD while MDMA increased
brain protein but had no significant effect on SOD.
Interestingly, both Nicotine and MDMA caused a reduction
in MDA and had no significant effect on GPx expression
level. Thus Nicotine or MDMA treatment elevated total brain
protein but had no effect on lipid peroxidation. Furthermore,
Nicotine-MDMA increased ALP significantly versus the con-
trol and other treatment groups; this was also associated with
significant effects on lipid peroxidation (increased MDA/
GPx) (Table 1).
Brain morphology
Motor neural axis Behavioural analysis (Rotarod, Y-Maze
and Parallel bar tests) show that MDMA treatment reduced
motor function while Nicotine increased motor function for
the same treatment duration. Going further, a combined
Nicotine-MDMA treatment had a less significant effect on
motor function when compared with the control and MDMA
treatment (Figs. 2 and 3). Sequel to these findings, we exam-
ined the general morphology of the motor neural axis (M1,
CPu and mfb) to show associated structural alterations
(histology) after treatment with Nicotine, MDMA and
Nicotine + MDMA. MDMA treatment induced degenerative
changes and cell loss in the M1 when compared to the control
(P < 0.01). In addition, prominent loss of fibres was observed
between the hippocampus and the Layer 6 of the M1 (Fig. 3c-
MDMA). Similarly, MDMA treatment caused striatal degen-
eration which was seen as a reduction in CPu cell count per
unit area (Fig. 3c, d MDMA). By contrast, Nicotine treatment
caused an increase in cell count in the CPu (P < 0.01); al-
though it decreasedM1 cell count (P < 0.001) when compared
with the control (Fig. 3d). Similar to the observations in
Nicotine treatment, a combined Nicotine-MDMA treatment
caused a reduction in M1 cell count (P < 0.001) but increased
CPu count (P < 0.001) versus the control (Fig. 3c, d).
Subsequent analysis of behavioural data (Nicotine and
Nicotine + MDMA) revealed that an increase in CPu cell
count was associated with an improvedmotor function despite
cell loss in the M1. This was further supported by the obser-
vations in MDMA treatment. A decline in cell count for M1
and CPu was recorded in this group (Fig. 3c, d); the animals
also showed a decline in motor function versus the
Nicotine and Nicotine-MDMA treatment groups
(Fig. 3a, b).
Hippocampus In behavioural analysis, MDMA, Nicotine
and Nicotine-MDMA treatment groups showed no significant
change in spatial working memory (Y-Maze; Fig. 4b) but re-
corded a significant decline in non-spatial working memory
function (NOR; Fig. 5a) when compared with the control.
Histological analysis of the hippocampus showed that
MDMA treatment induced a reduction in CA1 (P < 0.01)
and CA2 (P < 0.001) cell counts (degeneration) when com-
pared with the control. Interestingly, the CA3 and DG cell
counts were relatively unchanged versus the control
(Fig. 5b, c MDMA). By contrast, degenerative changes (cell
loss) were recorded in the CA3 (P < 0.001) and DG
(P < 0.001) of Nicotine treated animals, while no significant
change were recorded in CA1 and CA2 cell counts versus the
control (Fig. 5b, c Nicotine). Combined Nicotine-MDMA
Fig. 3 a-b Parallel bar test for motor function and coordination. a
Latency of turn (LOT) depicts the average duration in seconds taken by
animals in each group to complete a turn on two raised parallel bars
(motor function). The highest LOT was recorded in the Nicotine
treatment group when compared with the control (P < 0.05*). Similarly,
the Nicotine treatment recorded a significant increase in LOT when
compared with the MDMA treatment- which recorded the lowest LOT
(P < 0.001***). No significant change in LOT was seen between the
Nicotine treatment and Nicotine-MDMA treatment. Interestingly, the
Nicotine-MDMA treatment gave higher LOT scores when compared
with the MDMA treatment group. b The average time taken by animals
in a particular group to complete movement to either ends of the elevated
parallel bars. Decreased motor coordination was observed in the MDMA
(P < 0.01) and Nicotine-MDMA treated groups when compared with the
control (P < 0.05). In this test no significant difference in motor
coordination was observed between the MDMA, Nicotine and
Nicotine-MDMA treated animals. c-d Morphology of the motor cortex
(M1), striatum/basal ganglia (CPu) and the medial forebrain bundle
(mfb). c Cell loss was observed in the M1 of the treatment groups;
MDMA: P < 0.01, Nicotine: P < 0.001, Nicotine-MDMA: P < 0.001
when compared with the control. This was also associated with
degenerative changes between layer 6 (VI) and the hippocampus. The
most prominent change in CPu was observed in the Nicotine-MDMA
treatment group; this was seen as an increase in cell count per unit area
when compared with the control and other treatment groups (P < 0.001).
Degenerative changes were also observed in the CPu of the MDMA
treatment when compared with the control and the Nicotine treatment
group (P < 0.01). Hipp hippocampus, CPu striatum, M1 motor cortex,
mfbmedial forebrain bundle. Scale bars 1 mm and 100 μm. d Cell count
analysis (mean) and reconstruction of the M1 and CPu using Image J
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treatment caused a reduction in CA1 (P < 0.001), CA2
(P < 0.001) and DG (P < 0.05) cell counts while the CA3
remained unchanged when compared with the control
(Fig. 5b, c Nicotine-MDMA). These findings suggest selec-
tive susceptibility of the hippocampal cells and regional
variation in pattern of degeneration following the various
treatments. Interestingly, degenerative changes were seen in
one or more regions for all treatments and translated into a
decline in memory function for all treatment groups versus the
control (Fig. 5a).
D
(a)
(c)
(b)
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Discussion
Taken together the outcomes of this study suggests that
Nicotine, MDMA and Nicotine + MDMA treatment alters
the metabolism of the brain and the structure of neural systems
involved in motor function (M1, CPu and mfb) and memory
consolidation (hippocampus).Our findings suggests that the
mechanism of tissue damage and behavioural changes in
Nicotine-MDMA treatment are intrinsically linked with oxi-
dative stress patterns peculiar to each treatment category
(MDMA, Nicotine and Nicotine-MDMA). Furthermore, the
observed variations in oxidative stress involved changes in
brain total protein, ROS formation, phosphatase activity and
brain tissue lipid peroxidation. In this study, we have shown
the effects of these changes in neural system structure, motor
function and memory function after a prolonged treatment
period (10 days).
Behavioural changes The outcomes of this study show that
Nicotine, MDMA and Nicotine + MDMA treatment
(d)
Fig. 3 (continued)
Fig. 4 a-b Motor-Cognitive function determined in Y-Maze test. a The
total number of arm entries in the Y-Maze was determined to measure
exploratory motor function associated with spatial memory after an acute
treatment duration. No significant change was observed in exploratory
motor function when the treatment groups were compared with the
control. Similar to the outcomes of Rotarod and parallel bar tests for
motor function, the Nicotine treated animals showed a significant
exploratory motor function (number of arm entries) when compared
with the MDMA treated animals (P < 0.05*). b The percentage change
in Y-Maze arm alternations were plotted to determine the spatial working
memory index. No significant change in spatial working memory was
observed when the treatment groups were compared with the control for
this treatment duration (10 days)
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(b)
(a)
Fig. 5 a Novel object recognition test (recognition memory). Nicotine
(P < 0.05*), MDMA (P < 0.01**) and Nicotine-Cadmium (P < 0.01**)
treatment caused a decline in object recognition memory when compared
with the control. A more significant decline in memory function was
recorded in the MDMA treatment (P < 0.01**) when compared with
the control. Similarly, when MDMA was co-administered with
Nicotine, a further decline in memory function was also observed
versus the control (P < 0.01**). Nicotine treatment caused a less
significant decline in memory function versus the control (P < 0.05*).
No significance was found when a treatment group was compared with
the other treatment groups (Nicotine, MDMA or Nicotine-MDMA). b-c
Structure of the Hippocampus; CA1, CA2, CA3 and dentate gyrus (DG).
b MDMA treatment caused a reduction in cell count in the CA1
(P < 0.01) and CA2 (P < 0.001) regions of the hippocampus when
compared with the control. Interestingly, the CA3 and DG cell count
remained relatively unchanged. Nicotine treatment caused no significant
change CA1 and CA2 cell count but was characterized by a reduction in
CA3 (P < 0.001) and DG (P < 0.001) counts versus the control.
Combined Nicotine-MDMA treatment reduced the cell count in the
CA1 (P < 0.001), CA2 (P < 0.001) and DG (P < 0.05) while the CA3
count did not significantly change versus the control. In behavioural
analysis, the MDMA, Nicotine and Nicotine-MDMA treatment groups
were characterized by a reduction in object recognition memory function
and is linked with reduction in cell count for one or more regions of the
hippocampus. Hipp hippocampus, CPu striatum, M1 motor cortex, DG
dentate gyrus. Scale bars 1 mm and 100 μm. c Cell count analysis and
reconstruction of the CA1, CA2, CA3 and DG using Image J
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significantly induced changes in motor and cognitive func-
tions in mice after a period of prolonged exposure. Going
further, the observed behavioural changes were seen to cor-
roborate structural changes in the various brain regions con-
cerned with integration of motor function (CPu, M1 and mfb)
and memory function (Hippocampus). Through their effects
on various neurotransmitters in the central and peripheral ner-
vous systems, MDMA and Nicotine influences neuronal ac-
tivities and synaptic plasticity leading to impairments or en-
hancement of motor and memory related functions. The effect
of Nicotine and MDMA on 5-HT, Glutamergic, Cholinergic
and Dopaminergic neurotransmission is important in defining
the role of these drugs of addiction in the development of
neural functions in the mammalian brain during the
periadolescent period and how it influences cognition and
motor function in the early adolescent period of life. This
period is important in neural development as it represents
the final phase of synaptic consolidation of various brain net-
works governing these behaviours in the adolescent
(Galiñanes et al. 2009).
Other studies have shown that MDMA affects synaptic
plasticity at glutamergic and 5HT nerve endings in the hippo-
campus thereby impairing memory processing and consolida-
tion (Capela et al. 2009; Callaghan et al. 2006; Li et al. 2006).
In this study, periadolescent (P.21) mice treated with MDMA
showed a significant decline in non-spatial working memory
when examined in NOR in the early adolescence period (P.28-
P.31; Fig. 5a). Surprisingly, MDMA caused no significant
change in spatial working memory of these animals during
the early adolescence (Y-Maze; Fig. 4b). Similarly, MDMA
treatment significantly affected motor function in these ani-
mals. This was associated with a decline motor coordination
when compared with the control and the nicotine treated ani-
mals (Figs. 2, 3a, b). On the other hand, prolonged nicotinic
stimulation increased dopaminergic and 5HT activity through
the brain reward systems, thus, indirectly creating an excitato-
ry effect in the motor neural pathway (Collo et al. 2013;
Scherma et al. 2012). Increased motor coordination observed
in Nicotine treatment is often mediated through the central
effect of Nicotine on cholinergic receptors in the brain, and
its peripheral effects at neuromuscular junction and peripheral
cholinergic nerve endings (Wang et al. 2014). Similar to our
findings, other studies have reported an increase in motor
function due to a prolonged use of nicotine (Bruijnzeel et al.
2014; Lenoir et al. 2013). However, our results show that
prolonged treatment with Nicotine had no significant effect
on spatial working memory (Fig. 4b; Y-Maze) but significant-
ly reduced non-spatial working memory function (P < 0.05)
when compared with the control (Fig. 5a; NOR). In
subsequent analysis, we examined the effect of
Nicotine treatment on the histology of the hippocampus
and observed no change in CA1 and CA2 cell counts,
but a reduction in CA3 and DG cell counts (P < 0.001)
(Fig. 5b-Nicotine).
The effect of combined use of Nicotine and MDMA was
examined on motor function and memory function. Similar to
Nicotine or MDMA treatment, as discussed above, degenera-
tive changes were seen in M1 and CPu after a prolonged
(c)
Fig. 5 (continued)
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treatment duration. These changes, however, correlates with a
decline in motor function and coordination-similar to the pat-
tern seen inMDMA treatment but significantly lower than that
recorded by the nicotine treatment group. However, no signif-
icant change in motor function was observed when the
Nicotine-MDMA treatment group was compared with the
control (Figs. 2, 3a, b). Thus, Nicotine combined with
MDMA treatment enhanced motor function when compared
with MDMA treatment only (antagonizing effects) (Figs. 2, 3
and 4a). Gonzalez et al. (2005) and other groups have reported
(a)
(c) (d)
(e)
(b)
Fig. 6 a–d Colorimetric assay for oxidative stress markers and total
protein content in brain tissue homogenate. a Total protein analysis
show an increase in protein content after acute Nicotine or MDMA
treatment when compared with the control (P < 0.001). No significant
change in protein content was seen when the Nicotine-MDMA
treatment group was compared with the control. In addition, the
increase in total protein seen either in Nicotine or MDMA treatment
was significantly higher than value recorded for the Nicotine-MDMA
treatment group (P < 0.001). b An increase in superoxide dismutase
was observed only in the Nicotine treatment group versus the control
for the 10 days treatment duration (P < 0.05). MDMA and Nicotine-
MDMA treatment caused no significant change in SOD when
compared with the control. c Lipid peroxidation analysis show that
neither Nicotine nor MDMA treatment caused a significant change in
MDA when compared with the control. However, combined treatment
with Nicotine-MDMA caused a significant increase in lipid peroxidation
(MDA) when compared with the control (P < 0.05). dGPx analysis show
that either MDMA or Nicotine treatment caused a significant reduction in
GPx when compared with the control (P < 0.05). Nicotine-MDMA
treatment increased GPx level when compared to the MDMA or
Nicotine treatment groups (P < 0.001). No significant change in GPx
was recorded when the Nicotine-MDMA was compared with the
control. e Colorimetric assay for Alkaline Phosphatase (ALP). MDMA
treatment significantly increased brain tissue ALP when compared with
the control (P < 0.001). However, Nicotine treatment caused no
significant change versus the control. Nicotine-MDMA combined
treatment caused a significant increase in ALP when compared with the
control (P < 0.001), Nicotine (P < 0.001) and MDMA (P < 0.001)
treatment groups
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similar effects in experimental models of Nicotine and
MDMA treatment (Marston et al. 1999; van Wel et al. 2012).
Morphology In this study, histological examination of the
motor neural system after MDMA treatment revealed a reduc-
tion in cell count in the M1 (P < 0.01) and CPu (P < 0.01)
(Fig. 3c, d-MDMA). Similarly, loss of fibres was seen be-
tween the layer 6 of the M1 and the hippocampus (Fig. 3c,
d) after MDMA treatment. Subsequent analysis of behaviour-
al tests for motor function suggests that these degenerative
changes led to a reduction in motor coordination when the
MDMA treatment was compared with the control or
Nicotine treatment (Figs. 2, 3a, b). Similarly, MDMA also
caused structural changes in various parts of the hippocampus
which resulted in a decline in memory function (Fig. 5a–c;
MDMA). A reduction in cell count was observed in the CA1
(P < 0.01) and CA2 (P < 0.001) while the CA3 and DG
showed no change in cell count after a prolonged treatment
period (Fig. 5c, d).
Some of the observed histological changes in the CPu elu-
cidates the effect of nicotinic stimulation of motor function
and coordination. Structural changes post nicotine treatment
involved an increase in CPu cell count (P < 0.01) when the
nicotine treated group was compared with the MDMA treat-
ment group (Fig. 3c, d Nicotine). In support of these observa-
tions, we also recorded an increase in motor function and
coordination when nicotine treated mice were examined in
Rotarod, Y-Maze and Parallel bar tests for motor function
(Figs. 2, 3a, 4b). AlthoughNicotine treatment improvedmotor
function when combined with MDMA, this combination,
however, caused a significant decline in memory function
(Fig. 5a). This was in agreement with the outcome of memory
function tests for Nicotine or MDMA treatment as both treat-
ments caused a decline in memory function after a prolonged
treatment (Fig. 5a; Nicotine, MDMA). Similar to the preposi-
tion by Bakhtiar et al. (2014) and Gulley and Juraska (2013),
structural changes in the hippocampus were also associated
with the decline in memory function seen in the Nicotine,
MDMA and Nicotine + MDMA treatment group. Nicotine-
MDMA treatment was characterized by a reduction in CA1
(P < 0.001), CA2 (P < 0.001), DG (P < 0.05) cell counts while
the CA3 was relatively unchanged when compared with the
control (Fig. 5c). Our finding here in suggests that MDMA
treatment caused detrimental changes in neural structure and
behaviour when compared with the Nicotine-MDMA treat-
ment group.
Biochemical assay Aside the structural changes seen in the
various brain regions, we recorded variation in tissue metab-
olism and oxidative stress pattern induced by Nicotine,
MDMA and Nicotine +MDMA treatment. Nicotine treatment
caused an increase in total brain protein when compared with
the control group (Fig. 6b). To our surprise, the level of
ROS formation (%SOD; Fig. 6b) did not increase sig-
nificantly when compared with the control. As expected,
from these findings, an insignificant ROS formation was
associated with no significant change in lipid peroxida-
tion markers (GPx and MDA) versus the control
(Fig. 6c, d). Interestingly, MDMA treatment caused a
significant increase in ALP when compared with the
control, thus signifying certain level of nuclear damage
and abnormal membrane transport in the cells after
MDMA treatment. These findings suggest that MDMA
treatment induced degenerative changes through
excitotoxicity and increase in brain total protein rather
than lipid peroxidation. Although an increase in brain
protein (measured in CSF) has been attributed to in-
flammatory response (Orio et al. 2010), however, sever-
al other markers are required to confirm inflammation in
oxidative stress (in addition to an increase in total brain
protein). As a result of oxidative stress induced by
MDMA, degenerative changes were seen in the various
parts of the brain (Figs. 3c, 5b and 6c). This also trans-
lated into a decline in motor and memory function in
the animals (Figs. 5a and 3a).
Similar to our observations in MDMA treatment, in-
traperitoneally administered Nicotine increased the brain
total protein (Fig. 6a). However, contrary to MDMA
treatment outcomes, radical formation, depicted by an
increase in %SOD in brain tissue homogenate, was
highly significant in Nicotine treatment when compared
with the control. Despite the observed increase in ROS
formation (%SOD), no change in lipid peroxidation
(MDA/GPx) was observed when compared with the
control (similar to the MDMA treatment) (Fig. 6a–d).
In contrast to MDMA treatment, no significant change
in ALP was seen in the Nicotine treatment group when
compared with the control. Thus, we deduced that
Nicotine treatment increased protein content and ROS
while ALP and lipid peroxidation markers remained rel-
atively unchanged. Similar to our observations in
MDMA treatment, Nicotine also induced structural
Table 1 Schematic summary of ANOVA (with Bon Ferroni post-hoc
test) comparing nicotine and (or) MDMA treatment versus the control
and (or) other treatment groups
Treatment parameters Nicotine MDMA Nicotine-MDMA
Total protein ***(Increase) ***(Increase) NS
SOD *(Increase) NS NS
MDA NS NS *(Increase)
GPX *(Decrease) *(Decrease) ***(Increase)
ALP NS *(Increase) ***(Increase)
Statistical significance at 95 % confidence interval; *P < 0.05 and
***P < 0.001
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alterations in the motor area and hippocampus; causing
an increase in motor function and a decline in memory
function.
Ultimately, a combined Nicotine-MDMA treatment re-
duced the total protein content and SOD level. In addition,
Nicotine-MDMA treatment significantly increased the extent
of lipid peroxidation depicted by an increase in GPx and
MDA after a prolonged treatment. This was also linked with
an increase in ALP; depicting a wide rangemembrane damage
in combined treatment (Table 1). Contrary to what was ob-
served in Nicotine or MDMA treatment, a combined
Nicotine-MDMA treatment created opposing effects on lipid
peroxidation and brain total protein. A decline in brain total
protein was observed when the Nicotine-MDMA treatment
was compared with Nicotine or MDMA treatment
(P < 0.001) (Fig. 6a). Interestingly, this Nicotine-MDMA
treatment significantly increased MDA (P < 0.05) and GPx
(P < 0.001) (lipid peroxidation markers) when compared with
the control (Fig. 6c, d). From these outcomes, we deduced that
co-treatment with Nicotine-MDMA induced degeneration
through lipid peroxidation (MDA/ALP/GPx) while Nicotine
or MDMA treatment caused an increase in brain total protein.
As a result of the induced oxidative stress, the most prominent
structural change was observed in the CPu. Surprisingly, this
treatment group showed no significant change in motor func-
tion versus the control but recorded a decline in motor func-
tion when compared with the Nicotine and MDMA treatment
(Figs. 2 and 3).
Conclusion
In summary, these treatments induced oxidative stress and
cellular damage through various mechanisms. Nicotine or
MDMA treatment increased total brain protein but had no
significant effect on lipid peroxidation while Nicotine-
MDMA did not alter brain protein but increased the level of
lipid peroxidation (GPx and MDA). Nicotine treatment in-
creased motor function; MDMA reduced motor function
while Nicotine-MDMA did not significantly change motor
activity and coordination. Going further, the most prominent
change in the motor neural axis was observed in the
CPu and mfb. Nicotine, MDMA and Nicotine-MDMA
treatments significantly reduced memory function and
caused structural changes in one or more parts of the
hippocampus.
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